Cretostimogene Grenadenorepvec Clinical Studies
Our lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is currently in two phase three trials for the treatment of BCG unresponsive and intermediate risk NMIBC disease. It is also in Phase 2 study in combination with pembrolizumab in the same indication. Other types of bladder cancer are being evaluated with cretostimogene in combination with nivolumab. We are planning other studies in bladder cancer.
High-Risk, BCG-Unresponsive NMIBC (BOND-003)
High-Risk, BCG-Unresponsive NMIBC (CORE-001)
High-Risk, Cisplatin Ineligible MIBC (CORE-002)
High-Risk, BCG-Naive & BCG-exposed NMIBC (CORE-008)
Well Positioned to Tackle Different Stages of Bladder Cancer
Other studies are planned in the near future